“Œ“ú–{‘åkЋً}ƒtƒH[ƒ‰ƒ€
5ŒŽ20“úi‹àj 15:15`17:00@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ‘c•ƒ]@Œ³i‘æ52‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï@‘å‰ï’·j
-
- …àV@‰p—mi“ú–{_ŒoŠw‰ï@‘ã•\—Ž–j
Šî’²u‰‰
ЊQ‚ÌŒ»ê‚©‚ç
-
- ‚‹´@’qiŠâŽèˆã‰È‘åŠw_Œo“à‰Èj
-
- •l“o@•¶Žõi‚Í‚Ü‚Æ_Œo“à‰ÈƒNƒŠƒjƒbƒNj
ЊQ‚ÌŒ»ê‚©‚ç
-
- –Ø@³Žui“Œ–k‘åŠw_Œo“à‰Èj
ЊQ‚ÌŒ»ê‚©‚çiƒCƒ“ƒ^[ƒlƒbƒg’†Œpj
-
- ŠâŒ©@‰äiŠâŒ©_Œo“à‰Èˆã‰@j
ЊQ‚ÌŒ»ê‚©‚ç
-
- ‰Fì@‹`ˆêi•Ÿ“‡Œ§—§ˆã‰È‘åŠw_Œo“à‰Èj
ЊQŽx‰‡|s
-
- ’†“c@ŸŒÈii‘OjŒú¶˜J“ÈŽ¾•a‘Îô‰Ûj
Žw’蔌¾
ЊQŽx‰‡
-
- ŽR‘º@Ci•Ÿˆä‘åŠwˆãŠw•”•‘®•a‰@_Œo“à‰Èj
ЊQŽx‰‡
-
- ‰¬–ì@”üŒbŽqi–k—¢‘åŠw_Œo“à‰Èj
‘‡“¢˜_
ƒtƒƒA‚ðŒð‚¦‚½ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“
ƒy[ƒWƒgƒbƒv‚Ö↑
‘å‰ï’·u‰‰
- _Œo•Ï«Ž¾Š³‚Ì•ªŽq•W“IŽ¡—Âð–ÚŽw‚µ‚Ä
5ŒŽ18“úi…j 13:30`14:30@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ûü‹´@ºi–¼ŒÃ‰®‘åŠw–¼—_‹³Žö^“ŒŠC’†‰›•a‰@–¼—_‰@’·j
- ‰‰ŽÒF
- ‘c•ƒ]@Œ³i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
ƒy[ƒWƒgƒbƒv‚Ö↑
“Á•Êu‰‰
- “Á•Êu‰‰1
- Past, present, and future of polyglutamine expansion disease
5ŒŽ17“úi‰Îj 16:45`18:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- Š‹Œ´@–ÎŽ÷i—鎈ã—ÉȊw‘åŠw•ÛŒ’‰q¶Šw•”ˆã—ÕŸŽƒŠw‰Èj
- ‰‰ŽÒF
- Kenneth H. FischbeckiNeurogenetics Branch, NINDS, NIH, USAj
- “Á•Êu‰‰2
- 1•ªŽq‚©‚ç”]‚ÖF•¡ŽGƒVƒXƒeƒ€‚ð—‰ð‚·‚éVŠT”O
5ŒŽ17“úi‰Îj 16:45`18:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- –öàV@M•vi“Œ‹žH‰È‘åŠwˆã—Õی’Šw•”j
- ‰‰ŽÒF
- –ö“c@•q—Yi‘åã‘åŠw‘åŠw‰@¶–½‹@”\Œ¤‹†‰ÈCNICT ”]î•ñ’ÊMC—Œ¤QBiCj
ƒy[ƒWƒgƒbƒv‚Ö↑
ƒI[ƒvƒjƒ“ƒOƒZƒ~ƒi[
- ”]‚̉‘Y«‚ÌÅ‘OüF_Œo‹@”\‰ñ•œEƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì‹ß–¢—ˆ‚Ö‚Ì“W–]
5ŒŽ17“úi‰Îj 16:45`18:30@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- ‰Fì@‹`ˆêi•Ÿ“‡Œ§—§ˆã‰È‘åŠwˆãŠw•”_Œo“à‰ÈŠwj
-
- ”ö“¡@°•Fi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo¶‰»Šw•ª–ìj
1D”]‚Ì’·Šú‰Â‘Y«‚Ì•ªŽq‹@\
- ‰‰ŽÒF
- ”ö“¡@°•Fi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo¶‰»Šw•ª–ìj
2DŽ¥‹CŽhŒƒ‚É‚æ‚éƒqƒg’†•_Œo‚ł̉‘Y«‚Ì—U“±FQPS
- ‰‰ŽÒF
- ‰Fì@‹`ˆêi•Ÿ“‡Œ§—§ˆã‰È‘åŠwˆãŠw•”_Œo“à‰ÈŠwj
3D”]‘¹Œã‚Ì‹@”\‰ñ•œ‚Æ”]‚̉‘Y«i—Õ°j
- ‰‰ŽÒF
- •ž•”@Œ›–¾iX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j
ƒy[ƒWƒgƒbƒv‚Ö↑
“ú–{_ŒoŠw‰ï2010”N“x“è—ÑÜŽóÜŽÒµ‘Òu‰‰
5ŒŽ18“úi…j 13:10`13:30@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ‘c•ƒ]@Œ³i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
-
- …àV@‰p—mi“ú–{_ŒoŠw‰ï‘ã•\—Ž–C“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@”]_Œo•a‘ÔŠw•ª–ìj
ƒp[ƒLƒ“ƒ\ƒ“•a‚É‚¨‚¯‚é”F’m‹@”\áŠQ‚ÌŒ¤‹†F‚Æ‚‚ɎЉï“I”F’m‹@”\áŠQ‚ÆG“‘Ì‹@”\áŠQ‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä
- ‰‰ŽÒF
- ‰Í‘º@–žiº˜a‘åŠwˆãŠw•”“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
ƒy[ƒWƒgƒbƒv‚Ö↑
‹³ˆçu‰‰
- ‹³ˆçu‰‰1
- –¾“ú‚©‚ç–𗧂ˆã—ÈÀ‘SF_Œo“à‰Èf—Âɖ𗧂ƒƒfƒBƒG[ƒVƒ‡ƒ“ƒ‚ƒfƒ‹
5ŒŽ18“úi…j 7:45`8:20@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- ç—t@iiŽD–yŽR‚Ìã•a‰@j
- ‰‰ŽÒF
- ˆÀ“¡@“N˜Niˆ¤’mŒ§Œú¶˜AˆÀéX¶•a‰@_Œo“à‰Èj
- ‹³ˆçu‰‰2
- ‚æ‚‚í‚©‚éˆãŠwŒ¤‹†—Ï—Žwj
5ŒŽ18“úi…j 7:45`8:20@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j
- À’·F
- ‹gˆä@•¶‹Ïi“ŒŠC‘åŠw_Œo“à‰Èj
- ‰‰ŽÒF
- ”Ñ“‡@û€•Fi–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È¶–½—Ï—ˆÏˆõ‰ïj
- ‹³ˆçu‰‰3
- –TŽîᇫ_ŒoÇŒóŒQupdate
5ŒŽ18“úi…j 7:45`8:20@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- “c’†@ŒbŽqi‹à‘òˆã‰È‘åŠw_Œo“à‰ÈŠwj
- ‰‰ŽÒF
- Œ¢’Ë@‹MiŠò•Œ‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo“à‰ÈE˜V”NŠw•ª–ìj
- ‹³ˆçu‰‰4
- ‘½Œn“ˆÞkÇ‚Ì•Ï«‚Ì‚Í‚¶‚Ü‚è‚Í_Œo×–E‚©‚ç‚©ƒOƒŠƒA×–E‚©‚ç‚©
5ŒŽ18“úi…j 7:45`8:20@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- ‰Á“¡@M‰îi’¹Žæ‘åŠwˆãŠw•”•‘®”]Š²«Ž¾Š³Œ¤‹†Ž{Ý”]_Œo•a—•”–åj
‘½Œn“ˆÞkÇ\ƒVƒkƒNƒŒƒCƒ“‚Æ_Œo×–E•Ï«\
- ‰‰ŽÒF
- ‹g“c@áÁ—iˆ¤’mˆã‰È‘åŠw‰Á—îˆã‰ÈŠwŒ¤‹†Šj
‘½Œn“ˆÞkÇ‚Ì•Ï«‚Ì‚Í‚¶‚Ü‚è‚Í_Œo×–E‚©‚ç‚©ƒOƒŠƒA×–E‚©‚ç‚©FƒOƒŠƒA×–E
- ‰‰ŽÒF
- ŽR“c@Œõ‘¥i‘—§•a‰@‹@\‚³‚¢‚ª‚½•a‰@—Õ°Œ¤‹†•”j
- ‹³ˆçu‰‰5
- ‘O“ª‘¤“ª—t•Ï«ÇiFTLDj‚Ì•ª—Þ‚Æ•a‘Ôupdate
5ŒŽ18“úi…j 7:45`8:20@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- ‰ª–{@KŽsiŒQ”n‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_Œo“à‰ÈŠwj
- ‰‰ŽÒF
- ’†–ì@¡Ž¡iŽ©Ž¡ˆã‰È‘åŠw“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
- ‹³ˆçu‰‰6
- –Ɖu—}§Š³ŽÒ‚É‚¨‚¯‚é_ŒoŽ¾Š³
5ŒŽ19“úi–Øj 7:45`8:20@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- Œüˆä@‰hˆê˜Yi–¼ŒÃ‰®ˆã—ÃZƒ“ƒ^[_Œo“à‰Èj
- ‰‰ŽÒF
- ŠÝ“c@C“ñi‚ª‚ñEŠ´õǃZƒ“ƒ^[“s—§‹îž•a‰@”]_Œo“à‰Èj
- ‹³ˆçu‰‰7
- _ŒoŽ¾Š³‚Æ“œ½¶•¨ŠwFV‚½‚ȶ–½½‚Ì–ðŠ„
5ŒŽ19“úi–Øj 7:45`8:20@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j
- À’·F
- ‰Á“¡@ä•viŽRŒ`‘åŠwˆãŠw•”‘æ3“à‰Èj
- ‰‰ŽÒF
- •“¡@‘½’ØYi“¡“c•ÛŒ’‰q¶‘åŠwˆãŠw•””]_Œo“à‰ÈŠwj
- ‹³ˆçu‰‰8
- ŋ߂̈««”]Žîᇎ¡—ÂÌi•à
5ŒŽ19“úi–Øj 7:45`8:20@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- …’J@’q•Fi“ú–{‘åŠw‘‡ŠwŒ¤‹†Šj
- ‰‰ŽÒF
- Žá—Ñ@r•Fi–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_ŒoŠO‰ÈŠwj
- ‹³ˆçu‰‰9
- ”F’mÇ‚ÌBPSD‚Ì–ò•¨Ž¡—ÃF¸_‰È‚©‚ç‚̃ƒbƒZ[ƒW
5ŒŽ19“úi–Øj 7:45`8:20@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- —L‘º@Œö—Çi‘埕a‰@_Œo“à‰Èj
- ‰‰ŽÒF
- ‹´–{@‰qiŒF–{‘åŠwˆãŠw•”•‘®•a‰@_Œo¸_‰Èj
- ‹³ˆçu‰‰10
- ƒp[ƒLƒ“ƒ\ƒ“•a‚Ì”F’m‹@”\áŠQ‚Ìf•û
5ŒŽ19“úi–Øj 7:45`8:20@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- ¬Ž@K¶i–¼ŒÃ‰®Žs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo“à‰Èj
- ‰‰ŽÒF
- ‰Í‘º@–žiº˜a‘åŠwˆãŠw•”“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
- ‹³ˆçu‰‰11
- ”][ÇÄ”—\–hupdate
5ŒŽ19“úi–Øj 7:45`8:20@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- r–Ø@M•vié‹Êˆã‰È‘åŠw_Œo“à‰Èj
- ‰‰ŽÒF
- “c’†@k‘¾˜Yi•xŽR‘åŠw•‘®•a‰@_Œo“à‰Èj
- ‹³ˆçu‰‰12
- ”]MRI‚©‚ç•Ï«Ž¾Š³‚Ìf’f‚É”—‚é\•a—C—Õ°‚̑Δ䂩‚ç\
5ŒŽ20“úi‹àj 7:45`8:20@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- ´…@‹P•vi’é‹ž‘åŠwˆãŠw•”_Œo“à‰Èj
- ‰‰ŽÒF
- “n•Ó@G‹vi–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- ‹³ˆçu‰‰13
- _Œo“à‰Èˆã‚É•K—v‚Ȉâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒO
5ŒŽ20“úi‹àj 7:45`8:20@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- Œã“¡@‡i“Œ‹ž‘åŠw_Œo“à‰Èj
- ‰‰ŽÒF
- ‹g“c@–MLiMB‘åŠwˆãŠw•”_Œo“ï•aŠwuÀj
- ‹³ˆçu‰‰14
- ‚æ‚‚í‚©‚éCOI iconflict of interestj
5ŒŽ20“úi‹àj 7:45`8:20@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- ²ŒÃ“c@ŽO˜Yi“ªŽR•a‰@_Œo“à‰Èj
- ‰‰ŽÒF
- ‘]ª@ŽO˜Yi“ú–{ˆãŠw‰ï—˜‰v‘Š”½ˆÏˆõ‰ïi“¿“‡‘åŠw‘åŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”jj
- ‹³ˆçu‰‰15
- Ž©ŒÈ–Ɖu«_Œo‹ØÚ‡•”Ž¾Š³‚Ì•a‘Ô‚ÆŽ¡—Ã
5ŒŽ20“úi‹àj 7:45`8:20@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- ²‹´@Œ÷iˆ¤’mˆã‰È‘åŠw–¼—_‹³Žöj
- ‰‰ŽÒF
- –{‘º@Ÿi’·è‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È‘æˆê“à‰È_Œo“à‰Èj
- ‹³ˆçu‰‰16
- “«•Ð“ª’É‚Ì‘Îô‚ÆŽ¡—Ã
5ŒŽ20“úi‹àj 7:45`8:20@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- ’†“‡@Œ’“ñi’¹Žæ‘åŠwˆãŠw•”ˆãŠw‰È”]_Œoˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠw•ª–ìj
- ‰‰ŽÒF
- ´…@—˜•FiŒcœä‹`m‘åŠwˆãŠw•”_Œo“à‰Èj
ƒy[ƒWƒgƒbƒv‚Ö↑
ƒzƒbƒgƒgƒsƒbƒNƒX
- ƒzƒbƒgƒgƒsƒbƒNƒX1@Neuromyelitis opticaiNMOj‚Ì‚·‚ׂÄ
5ŒŽ18“úi…j 8:30`9:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- Ž…ŽR@‘×li‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[•a‰@j
- ‰‰ŽÒF
- “¡Œ´@ˆê’ji“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È‘½”«d‰»ÇŽ¡—ÊwŠñ•uÀj
- ƒzƒbƒgƒgƒsƒbƒNƒX2@‘½”«d‰»Ç‚ÌÅV‚Ì•a‘Ô‚ÆŽ¡—Ã
5ŒŽ18“úi…j 9:30`10:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- Ö“c@F•Fi‹ž“s–¯ˆã˜A’†‰›•a‰@_Œo“à‰Èj
Pathophysiology of progressive multiple sclerosis: studies in a genetically manipulated murine model
- ‰‰ŽÒF
- David PleasureiInstitute for Pediatric Regenerative Research and Department of Neurology, UC Davis, USAj
‘½”«d‰»Ç‚ÆÁ‰»ŠÇ–Ɖu
- ‰‰ŽÒF
- ŽR‘º@—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†Š–ƉuŒ¤‹†•”j
- ƒzƒbƒgƒgƒsƒbƒNƒX3@_Œo“à‰ÈŽ¡—ÃKƒCƒhƒ‰ƒCƒ“G‚Ä‚ñ‚©‚ñ
5ŒŽ18“úi…j 10:30`11:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- •½“c@KˆêiàÕ‹¦ˆã‰È‘åŠw_Œo“à‰Èj
- ‰‰ŽÒF
- ’Ò@’åriŽY‹Æˆã‰È‘åŠw_Œo“à‰Èj
- ƒzƒbƒgƒgƒsƒbƒNƒX4@ƒp[ƒLƒ“ƒ\ƒ“•aŽ¡—ÃKƒCƒhƒ‰ƒCƒ“2011
5ŒŽ19“úi–Øj 8:30`9:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ‚‹´@—Ç•ãi‹ž“s‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È—Õ°_ŒoŠwj
- ‰‰ŽÒF
- •“c@“Äi“Œ–k‘åŠw•a‰@_Œo“à‰Èj
- ƒzƒbƒgƒgƒsƒbƒNƒX5@Ž©ŒÈR‘Ì‚©‚ç‚Ý‚½ƒjƒ…[ƒƒpƒ`[
5ŒŽ19“úi–Øj 9:30`10:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ŒIŽR@Ÿi”]_ŒoƒZƒ“ƒ^[‘å“c‹L”O•a‰@j
- ‰‰ŽÒF
- “í@ii‹ß‹E‘åŠw_Œo“à‰Èj
- ƒzƒbƒgƒgƒsƒbƒNƒX6@_Œo“à‰ÈŽ¡—ÃKƒCƒhƒ‰ƒCƒ“G‘½”«d‰»Ç
5ŒŽ19“úi–Øj 10:30`11:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- –쑺@‹±ˆêié‹Êˆã‰È‘åŠw‘‡ˆã—ÃZƒ“ƒ^[_Œo“à‰Èj
- ‰‰ŽÒF
- ‹g—Ç@ˆêi‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@_Œo“à‰Èj
- ƒzƒbƒgƒgƒsƒbƒNƒX7@RNA splicingˆÙí‚Æ_ŒoŽ¾Š³
5ŒŽ19“úi–Øj 13:15`14:05@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ‰ºà_@riŽD–yˆã‰È‘åŠw_Œo“à‰Èj
- ‰‰ŽÒF
- ‘å–ì@‹ÔŽii–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œoˆâ“`î•ñŠwj
- ƒzƒbƒgƒgƒsƒbƒNƒX8@ALS‚Ì•a—FÅV‚Ì’mŒ©
5ŒŽ20“úi‹àj 8:30`9:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- Š‹Œ´@–ÎŽ÷i—鎈ã—ÉȊw‘åŠw•ÛŒ’‰q¶Šw•”ˆã—ÕŸŽƒŠw‰Èj
- ‰‰ŽÒF
- ‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
- ƒzƒbƒgƒgƒsƒbƒNƒX9@_Œo“à‰ÈŽ¡—ÃKƒCƒhƒ‰ƒCƒ“G”F’mÇ
5ŒŽ20“úi‹àj 9:30`10:20@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ´…@‹P•vi’é‹ž‘åŠwˆãŠw•”_Œo“à‰Èj
- ‰‰ŽÒF
- ’†“‡@Œ’“ñi’¹Žæ‘åŠwˆãŠw•”ˆãŠw‰È”]_Œoˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠw•ª–ìj
ƒy[ƒWƒgƒbƒv‚Ö↑
ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“
- ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“1
Lee Silverman Voice Treatment; Rehabilitative Therapy for People with Parkinsonfs
5ŒŽ19“úi–Øj 10:45`11:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- ‘º“c@”ü•äi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[j
- ‰‰ŽÒF
- Cynthia M FoxiNational Center for Voice and Speechj
- ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“2@ƒp[ƒLƒ“ƒ\ƒ“ÇŒó‚ð•û’öŽ®‚Å‰ð‚±‚¤
5ŒŽ19“úi–Øj 14:45`16:45@1B‰ïêi1†ŠÙ3ŠK‰ï‹cŽº131{132j
- À’·F
- ¬–쎛@Gi¼‘½‰ê•a‰@_Œo“à‰Èj
- ‰‰ŽÒF
- ²ŒÃ“c@ŽO˜Yi‘—§•a‰@‹@\“ªŽR•a‰@j
- ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒZƒbƒVƒ‡ƒ“3@_ŒoƒCƒ[ƒWƒ“ƒOŽè–@‚ð—p‚¢‚½Šç”F’m‹@\‚̉ð–¾
5ŒŽ19“úi–Øj 14:45`16:45@1C‰ïêi1†ŠÙ3ŠK‰ï‹cŽº133{134j
- À’·F
- ”ò¼@ÈŽOi‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@”]Œ¤—Õ°_Œo¶—j
- ‰‰ŽÒF
- Š`–Ø@—²‰îi¶—ŠwŒ¤‹†Š“‡¶—Œ¤‹†Œnj
ƒy[ƒWƒgƒbƒv‚Ö↑
AAN-JSN Joint Symposiumi“ú•Ä_ŒoŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€j
- Keynote Session
5ŒŽ18“úi…j 14:30`15:00@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ‹ààV@ˆê˜Yi“ú–{Šwp‰ï‹c‰ï’·C‘Ûˆã—ÕŸŽƒ‘åŠw‘åŠw‰@‘åŠw‰@’·j
- JS-K-1
- The Japanese Society of Neurology and the American Academy of Neurology:Response to Global Imperatives
Robert GriggsiPresident of American Academy of Neurology; Department of Neurology, University of Rochester School of Medicine and Dentistry, USAj
- JS-K-2
- American Academy of Neurology (AAN) and Japanese Society of Neurology (JSN) FBeyond the Pacific
…àV@‰p—mi“ú–{_ŒoŠw‰ï‘ã•\—Ž–C“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@”]_Œo•a‘ÔŠw•ª–ìj
- 1DALS
5ŒŽ18“úi…j 15:00`16:45@1A‰ïêi1†ŠÙ2ŠKƒZƒ“ƒ`ƒ…ƒŠ[ƒz[ƒ‹j
- À’·F
- ‘c•ƒ]@Œ³i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
-
- Don W. ClevelandiLudnig institute, University of California at San Diego, USAj
- JS-1-1
- Clinical or Patient-Oriented Research to Find the Pathogeneses and Cause of ALS
ŽO–{@”ŽiDepartment of Neurology, Columbia University, USAj
- JS-1-2
- The basis for selective neuronal vulnerability in ALS:mechanisms and therapy for ALS
Don W. ClevelandiLudwig Institute, University of California at San Diego, USAj
- JS-1-3
- Oligodendroglia are an unexpected major contributor to ALS and Neurodegeneration
Jeffrey D. RothsteiniJohns Hopkins University, USAj
- JS-1-4
- Optineurin in ALS
ìã@GŽjiL“‡‘åŠwŒ´”š•úŽËüˆã‰ÈŠwŒ¤‹†Šj
- JS-1-5
- Failure of RNA editing and the pathogenesis of ALS
Šs@Li“Œ‹ž‘åŠw_Œo“à‰Èj
- 2DƒAƒ‹ƒcƒnƒCƒ}[•a
5ŒŽ18“úi…j 15:00`16:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- Šâ’Ø@ˆÐi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo•a—Šwj
-
- Michael W. WeineriDepartment of Radiology, San Francisco VA Medical Center/UCSF, USAj
- JS-2-1
- Mechanisms and Treatment of Neuronal Dysfunction in Models of Alzheimerfs Disease
Lennart MuckeiGladstone Institute of Neurological Disease and UCSF, USAj
- JS-2-2
- Biomakers for Predicting and Monitoring Progression of Alzheimerfs Disease:The Alzheimerfs Disease Neuroimaging Initiative
Michael W. WeineriDepartment of Radiology, San Francisco VA Medical Center/UCSF, USAj
- JS-2-3
- Molecular pathology and disease-modifying therapies for Alzheimerfs disease
Šâ’Ø@ˆÐi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo•a—Šwj
- JS-2-4
- The future of Alzheimerfs disease:opportunities and challenges in drug development
“¡–{@—zŽqiƒtƒ@ƒCƒU[»–òŠ”Ž®‰ïŽÐŠJ”•”j
ƒy[ƒWƒgƒbƒv‚Ö↑
|
- East Asian Neurology Forum ‚ÍThe Movement Disorder Society ‚ÌŒö”FƒvƒƒOƒ‰ƒ€‚Å‚·B
|
East Asian Neurology Forum
- Keynote Session
5ŒŽ19“úi–Øj 13:10`14:40@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- ЯԼ@~iDepartment of Neurology, University of Iowa, USAj
-
- ‚‹´@—Ç•ãi‹ž“s‘åŠw_Œo“à‰Èj
- EA-K-1
- Message from the WCN to the East Asian Neurology
Mostafa El Alaoui FarisiPresident of the 20th World Congress of Neurology, Marrakesh, 2011, Moroccoj
- EA-K-2
- Role of the CSN in East Asia
Liying CuiiFormer President of the Chinese Society of Neurology, Chinaj
- EA-K-3
- Role of the KNA in East Asia
Beom S. JeoniInternational Delegate of the Korean Neurological Association, Koreaj
- EA-K-4
- Role of the JSN in East Asia
…àV@‰p—mi“ú–{_ŒoŠw‰ï‘ã•\—Ž–C“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@”]_Œo•a‘ÔŠw•ª–ìj
- EA-K-5
- Žw’蔌¾
Š@—´™Zi¢ŠE_ŒoŠw˜A–¿—Ž–C“¿“‡‘åŠw_Œo“à‰Èj
5ŒŽ19“úi–Øj 14:40`16:45@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- ŽR–{@Œõ—˜i쌧—§’†‰›•a‰@_Œo“à‰Èj
-
- Beom S. JeoniSeoul National University Hospital, Koreaj
- Žw’蔌¾
- Accelerating the Cure for Parkinsonfs Disease:MJFF Mission and Funding Philosophy
Mark FrasieriResearch Programs, Michael J Fox Foundation for Parkinsonfs Research, USAj
ParkinsonismFup-to-date
- EA-1-1
- Neuroimaging and Diagnosis of Parkinsonism
Chong S. LeeiASAN Medical Center, Koreaj
- EA-1-2
- Treatment of early Parkinsonfs disease
Louis TaniNational Neuroscience Institute, Singaporej
- EA-1-3
- Treatment of advanced Parkinsonfs disease
Shu-Leong HoiUniversity of Hong Kong Queen Mary Hospital, Hong Kongj
- EA-1-4
- Non-motor feature in Parkinsonfs disease
‘O“c@“N–çiH“cŒ§—§”]ŒŒŠÇŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰ÈŠwŒ¤‹†•”j
- EA-1-5
- Genetics of Parkinsonfs disease in Asia
Chin-Song LuiChang Gung Medical Center at Linkou, Taiwanj
ƒy[ƒWƒgƒbƒv‚Ö↑
|
- East Asian Neurology Forum: Poster Session ‚ÍThe Movement Disorder Society ‚ÌŒö”FƒvƒƒOƒ‰ƒ€‚Å‚·B
|
East Asian Neurology Forum: Poster Session
5ŒŽ18“úi…j 16:45`17:30iŽ©—R“¢˜_j/17:30`18:30iƒ|ƒXƒ^[”•\j
1Eiƒ|ƒXƒ^[‘æ1j‰ïêi1†ŠÙ1ŠKƒCƒxƒ“ƒgƒz[ƒ‹j
- À’·F
- ‘åŒF@‘×”Vi‡“V“°‘åŠwˆãŠw•”•‘®Ã‰ª•a‰@”]_Œo“à‰Èj
- EP-A-1
- The effect of IV amantadine on freezing of gaitifogjresistant to dopaminergic therapy
Young Eun KimiDepartments of Neurology and Movement Disorder Center, College of Medicine, Seoul National Universityj
- EP-A-2
- Detecting falls and freezing with motion recorder in Parkinsonfs disease patients under daily life condition
Yasuyuki OkumaiDepartment of Neurology, Juntendo University Shizuoka Hospitalj
- EP-A-3
- Relative significance of SCA2, SCA3 and SCA17 in Korean patients with parkinsonism
Ji Young YuniDepartment of Neurology, Seoul National University Hospitalj
- EP-A-4
- First case with X-linked dystonia-parkinsonismiXDP: DYT-3eLubagfjimproved by bilateral pallidum stimulation in Japan
Katsuo KimuraiDepartment of Neurology, Tokyo Metropolitan Neurological Hospitalj
- EP-A-5
- Role of serotonin receptor 2A gene variants in the impulsive compulsive behaviors in PD
Jee-Young LeeiDepartment of Neurology, College of Medicine, Seoul National University Boramae Hospital; Parkinson Study Group, Seoul National University Hospitalj
- EP-A-6
- Improvement of pathological gambling following subthalamic nucleus stimulation for Parkinsonfs disease
Hidemoto SaikiiDepartment of Neurology, Kitano Hospital, The Tazuke Kofukai Medical Institutej
- EP-A-7
- The Benefit of STN|DBS on Pain in Parkinson Disease: A 2|Year Follow|Up Study
Han-Joon KimiDepartments of Neurology and Movement Disorder Center, and Neuroscience Research Institute, BK21, College of Medicine, Seoul National University Hospital, Seoul, Korea; Parkinson Disease Study Group, Seoul National University Hospital, Seoul, Koreaj
- À’·F
- •ž•”@MFi‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
- EP-B-1
- Compound heterozygous rearrangements of parkin in early-onset parkinsonism
Yuanzhe LiiResearch Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo Universityj
- EP-B-2
- Treatment of AD model mice with TAPIR-like monoclonal antibody 3.4A10
Haifeng JiniResearch Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine; Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate School of Medicinej
- EP-B-3
- The role of dynactin-1 in autophagy: a regulator for autophagosome-lysosome fusion
Zhe HuangiDepartment of Neurology, Nagoya University Graduate School of Medicinej
- EP-B-4
- Prospective observations of cognitive function and plasma homocysteine level in Parkinsonfs disease
Tetsuya MaedaiDepartment of Neurology, Research Institute for Brain and Blood Vessels Akitaj
- EP-B-5
- Hsp90 inhibitors ameliorates polyglutamine-mediated motor dysfunction in SBMA models
Qiang QiangiDepartment of Neurology, Nagoya University Graduate School of Medicinej
- EP-B-6
- Clinical correlates of anterior flexion of the thoracolumbar spine in patients with Parkinsonfs disease
Kenichi KashiharaiDepartment of Neurology, Okayama Kyokuto Hospitalj
ƒy[ƒWƒgƒbƒv‚Ö↑
ƒVƒ“ƒ|ƒWƒEƒ€
- ƒVƒ“ƒ|ƒWƒEƒ€1
- BAD ‚Í‚Ç‚¤’è‹`‚µC‘Ήž‚·‚é‚©GŠe‘‚Ìl‚¦•û
5ŒŽ19“úi–Øj 13:15`14:45@1B‰ïêi1†ŠÙ3ŠK‰ï‹cŽº131{132j
- À’·F
- ŽÂŒ´@Kli‘‰ÆŒö–±ˆõ‹¤Ï‘g‡˜A‡‰ï—§ì•a‰@_Œo“à‰Èj
-
- ’I‹´@‹I•vié‹Êˆã‰È‘åŠw‘Ûˆã—ÃZƒ“ƒ^[”]‘²’†“à‰Èj
- SY-01-1
- ‰ä‚ª‘‚É‚¨‚¯‚éBAD ‚ÌŒ»óiJ|BAD Registry ‚̉ðÍ‚©‚çj
¯–ì@°•Fi“Œ‹ž“s϶‰ï’†‰›•a‰@_Œo“à‰Èj
- SY-01-2
- Branch atheromatous disease:an important cause of small subcortical infarction in Asia
Jong Sung KimiMedical college, University of Ulsan; Department of Neurology, Asan Medical Center; Stroke Center, Asan Medical Center, Koreaj
- SY-01-3
- Branch atheromatous disease:prognosis and management. The SPS3 experience
Oscar BenaventeiDivision of Neurology, University of British Columbia, Canadaj
- ƒVƒ“ƒ|ƒWƒEƒ€2
- ƒAƒ‹ƒcƒnƒCƒ}[•a‚Ì•ªŽqŽ¡—Ãí—ªFV‚µ‚¢Ž‹“_‚ð‹‚ß‚Ä
5ŒŽ19“úi–Øj 13:15`14:45@1C‰ïêi1†ŠÙ3ŠK‰ï‹cŽº133{134j
- À’·F
- ‘唪–Ø@•Ûi‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@”]Œ¤_Œo“à‰Èj
-
- Œ´@‰p•vi²‰ê‘åŠwˆãŠw•”_Œo“à‰Èj
- SY-02-1
- ×–E“àƒAƒ~ƒƒCƒhƒÀ‚¨‚æ‚ÑŽ_‰»ƒXƒgƒŒƒX‚ð•W“I‚Æ‚·‚鎡—ÖòFƒAƒ|ƒ‚ƒ‹ƒtƒBƒ“
‘唪–Ø@•Ûi‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@”]Œ¤_Œo“à‰Èj
- SY-02-2
- ƒAƒ‹ƒcƒnƒCƒ}[•a‚ÆŠ¿•ûŽ¡—Ã
Œ´@‰p•vi²‰ê‘åŠwˆãŠw•”_Œo“à‰Èj
- SY-02-3
- •ªŽqƒVƒƒƒyƒƒ“—U“±Ü‚̃Aƒ‹ƒcƒnƒCƒ}[•aŽ¡—Âւ̉ž—p
H“¡@‹ªi‘åã‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È¸_ˆãŠw‹³Žºj
- SY-02-4
- ƒAƒ~ƒƒCƒhƒÀ‚Ì“Å«ƒ^[ƒ“\‘¢‚ð”FŽ¯‚·‚éR‘Ì‚ÌŠJ”
“ü]@ˆê_i‹ž“s‘åŠw”_ŠwŒ¤‹†‰ÈH•i¶•¨‰ÈŠwêUj
- ƒVƒ“ƒ|ƒWƒEƒ€3
- ’E‘«Ž¾Š³‚É‚¨‚¯‚éƒOƒŠƒAŠÔ‚¨‚æ‚уOƒŠƒAEƒjƒ…[ƒƒ“ŠÔ‘ŠŒÝì—p‚Ì”j’]
5ŒŽ19“úi–Øj 13:15`14:45@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j
- À’·F
- ‹g—Ç@ˆêi‹ãB‘åŠw_Œo“à‰Èj
-
- Žà‘º@–¾¶i–¼ŒÃ‰®‘åŠwŠÂ‹«ˆãŠwŒ¤‹†Š_Œo–Ɖu•ª–ìj
- SY-03-1
- _Œo‰ÈŠw‚©‚猩‚½’E‘«Ž¾Š³‚É‚¨‚¯‚é–Ɖu×–EEƒOƒŠƒAEƒjƒ…[ƒƒ“ŠÔ‘ŠŒÝì—p‚̈Ùí
…–ì@“N–çi–¼ŒÃ‰®‘åŠwŠÂ‹«ˆãŠwŒ¤‹†Š_Œo–Ɖu•ª–ìj
- SY-03-2
- MS/NMO‚̃‚ƒfƒ‹‚©‚ç‚Ý‚½’E‘«Ž¾Š³‚É‚¨‚¯‚é–Ɖu×–EEƒOƒŠƒAEƒjƒ…[ƒƒ“ŠÔ‘ŠŒÝì—p‚̈Ùí
’†’Ò@—TŽii‘åã‘åŠw_Œo“à‰Èj
- SY-03-3
- Ž‹_ŒoÒ‘‰ŠC‘½”«d‰»ÇCBalo•a‚É‚¨‚¯‚éƒAƒXƒgƒƒTƒCƒgáŠQ‚Ì“Á’¥
¼‰º@‘ñ–çi‹ãB‘åŠw—Õ°_Œo–ƉuŠwj
- ƒVƒ“ƒ|ƒWƒEƒ€4
- _Œo“à‰È—̈æ‚É‚¨‚¯‚é‘O•ûŒü“IƒRƒz[ƒgŒ¤‹†‚©‚猩‚¦‚Ä‚«‚½‚à‚Ì
5ŒŽ19“úi–Øj 13:15`14:45@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- •ô¼@ˆê•vi‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[j
-
- ŽáŽR@‹gOiº˜a‘åŠw–¼—_‹³Žöj
- SY-04-1
- ‹ØƒWƒXƒgƒƒtƒB[ƒŒƒWƒXƒgƒŠ[iRemudyjGŠ³ŽÒ‚ÌŽ©”“I“o˜^ƒVƒXƒeƒ€\’z‚ÆŠCŠO‚Ƃ̘AŒg
’†‘º@Ž¡‰ëi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj
- SY-04-2
- JaCALSGALS‚ÌisC—\Œã‹K’èˆöŽq
”M“c@’¼Ž÷i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-04-3
- ”F’mǂ̃Rƒz[ƒgŒ¤‹†F‹vŽR’¬Œ¤‹†
´Œ´@—Ti‹ãB‘åŠwŠÂ‹«ˆãŠw•ª–ìj
- SY-04-4
- JAMSACFMSA‚ɑ΂·‚édisease|modifying therapyŽÀŒ»‚Ì‚½‚ß‚Ì—Õ°Ž¡Œ±ƒfƒUƒCƒ“
Žsì@–í¶ŽqiJAMSACiJapan MSA research consortiumjC“Œ‹ž‘åŠw_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€5
- ‹ØƒWƒXƒgƒƒtƒB[V‹KŽ¡—Ö@ŠJ”‚ÌÅ‘Oü
5ŒŽ19“úi–Øj 13:15`14:45@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j
- À’·F
- »“c@–FGiìèˆã‰È‘åŠw_Œo“à‰ÈŠwj
-
- ¼‘º@Šìˆê˜Yi’é‹ž‘åŠwˆãŠw•”_Œo“à‰Èj
- SY-05-1
- ƒfƒ…ƒVƒFƒ“ƒkŒ^‚ɑ΂·‚éƒGƒLƒ\ƒ“ƒXƒLƒbƒvŽ¡—Ã
•“c@Lˆêi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ˆâ“`ŽqŽ¾Š³Ž¡—ÃŒ¤‹†•”j
- SY-05-2
- •ŸŽRŒ^‹ØƒWƒXƒgƒƒtƒB[‚ÌV‚½‚È•a‘ÔEŽ¡—Ãí—ª
ŒË“c@’BŽji_ŒË‘åŠw_Œo“à‰Èj
- SY-05-3
- Large‚É‚æ‚郿|ƒWƒXƒgƒƒOƒŠƒJƒmƒpƒ`[‚ɑ΂·‚鎡—Ö@‚ÌŠJ”
Ä“¡@Žj–¾i’é‹ž‘åŠw_Œo“à‰Èj
- SY-05-4
- œŠi‹ØĶŽ¡—Ã
‘åàV@—Tiìèˆã‰È‘åŠw•‘®•a‰@_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€6
- Brain|machine interface‚Í‚Ç‚±‚܂ʼn”\‚©H
5ŒŽ19“úi–Øj 13:15`14:45@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- •ÐŽR@‘טNi“ú–{ˆã‰È‘åŠw_ŒoEt‘ŸEäPŒ´•aƒŠƒEƒ}ƒ`“à‰È•”–åj
-
- –{“c@Šwi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[j
- SY-06-1
- Ò‘‘¹Œã‚Ì‹@”\‰ñ•œ‹@˜‚̉𖾂Ƌ@”\‚ð•â‚¤lH_ŒoÚ‘±
¼‘º@K’ji¶—ŠwŒ¤‹†Š”F’ms“®”’B‹@\Œ¤‹†•”–åj
- SY-06-2
- Real|time NIRS‚É‚æ‚éƒjƒ…[ƒƒtƒB[ƒhƒoƒbƒN‚ð—p‚¢‚½_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“
ŽOŒ´@‰ëŽjiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”E_Œo“à‰Èj
- SY-06-3
- _ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚É‚¨‚¯‚é”ñNP“IBrain-machine interface‚̉”\«
‹ê@ˆêiŒcœä‹`m‘åŠw—HŠw•”¶–½î•ñŠw‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€7
- Atypical types of dementia”ñ“TŒ^”F’mÇ
5ŒŽ19“úi–Øj 8:30`10:30@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- Šâ“c@~i“Œ‹ž‘åŠwˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
-
- ‰Í‘º@–žiº˜a‘åŠw“à‰ÈŠwuÀ_Œo“à‰ÈŠw•”–åj
- SY-07-1
- Dementia‚Ì•ªŽq•a‘ÔFEpigeneticsŒ¤‹†‚©‚ç
Šâ“c@~i“Œ‹ž‘åŠwˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
- SY-07-2
- ”ñ“TŒ^”F’mÇ‚Ö‚Ì—Õ°“IƒAƒvƒ[ƒ`
—é–Ø@‹§ŽqiŽRŒ`‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È‚ŽŸ”]‹@”\áŠQŠwj
- SY-07-3
- ”玿«‹U«‹…–ƒáƒ‚É‚æ‚锘báŠQ‚Ŕǂ·‚é_Œo•Ï«Ž¾Š³
ÎŒ´@Œ’Žiiº˜a‘åŠw•a‰@_Œo“à‰Èj
- SY-07-4
- Dementia with motor neuron disease
Michael J. StrongiDepartment of Clinical Neurological Sciences, The Schulich School of Medicine & Dentistry, The University of Western Ontario, Canadaj
- ƒVƒ“ƒ|ƒWƒEƒ€8
- ’É‚Ý‚ÌÅV‚Ì•a‘Ô‚ÆŽ¡—Ã
5ŒŽ19“úi–Øj 13:15`14:45@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- ‹“c@‹Giˆ¤’mˆã‰È‘åŠwŠwÛ“I’ɂ݃Zƒ“ƒ^[j
-
- ”nê@³”ViÂXŒ§—§’†‰›•a‰@_Œo“à‰Èj
- SY-08-1
- Neuropathic pain-definition, mechanisms diagnosis and management
Ralf BaroniDivision of Neurological Pain Research and Therapy, Department of Neurologie, Univesitäetsklinikum Schleswig-Holstein, Germanyj
- SY-08-2
- Ò‘‘“àŽîá‡pŒã‚ÌÒ‘áŠQ«áu’É‚Ì•a‘Ô
’†‘º@‰ë–çiŒcœä‹`m‘åŠwˆãŠw•”®Œ`ŠO‰Èj
- SY-08-3
- _ŒoáŠQ«áu’É‚Ì•Û‘¶“IŽ¡—Ã
‹“c@‹Giˆ¤’mˆã‰È‘åŠwŠwÛ“I’ɂ݃Zƒ“ƒ^[j
- ƒVƒ“ƒ|ƒWƒEƒ€9
- ”玿‰º«ŒŒŠÇáŠQ‚Ì•a‘Ô‚ÆŽ¡—Ã
5ŒŽ19“úi–Øj 13:15`14:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- “à–ì@½iŒF–{‘åŠw‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•”_Œo“à‰ÈŠw•ª–ìj
-
- •y–{@G˜aiŽOd‘åŠw_Œo•a‘Ô“à‰ÈŠw•ª–ìj
- SY-09-1
- ”玿‰ºŒŒŠÇ«”F’mÇF”F’mÇŽ¾Š³‚É‚¨‚¯‚éˆÊ’u‚¯
•y–{@G˜aiŽOd‘åŠw_Œo•a‘Ô“à‰ÈŠw•ª–ìj
- SY-09-2
- TGF|ƒÀƒtƒ@ƒ~ƒŠ[ƒVƒOƒiƒ‹‚̈Ùí‚Æ”]¬ŒŒŠÇ•a|CARASIL‚Ì•ªŽq•a‘Ԃ̉ðÍ‚©‚ç
¬–쎛@—iVŠƒ‘åŠw”]Œ¤‹†Š•‘®¶–½‰ÈŠwƒŠƒ\[ƒXŒ¤‹†ƒZƒ“ƒ^[”]Ž¾Š³ƒŠƒ\[ƒX‰ðÍ•”–åj
- SY-09-3
- ”玿‰º«ŒŒŠÇáŠQ‚Ì•a‘Ô‚ÆŽ¡—Ã\CADASIL
“à–ì@½iŒF–{‘åŠw‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•”_Œo“à‰ÈŠw•ª–ìj
- ƒVƒ“ƒ|ƒWƒEƒ€10
- —Õ°‚ÆŒ¤‹†‚ɖ𗧂ÂÅV‚ÌMRIŠw
5ŒŽ19“úi–Øj 13:15`14:45@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j
- À’·F
- –Ø@–ÎŽ÷i‡“V“°‘åŠw•úŽËüˆãŠwuÀj
-
- X@‰x˜Ni“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È‚ŽŸ”]‹@”\áŠQŠw•ª–ìj
- SY-10-1
- MRI‚ÅŒ©‚¦‚é‚à‚ÌG3.0T‚Æ1.5T‚Ƃ̑Δä
ŽO–Ø@K—Yi‘åãŽs—§‘åŠw•úŽËü‰Èj
- SY-10-2
- _Œo“à‰È—̈æ‚É‚¨‚¯‚éMRI‚ð—p‚¢‚½—Õ°Œ¤‹†|1–‡‚̉摜‚ð‚Ç‚¤•]‰¿‚·‚é‚©|
ˆÉ“¡@²ˆêiç—t‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@ˆãŠw‹³ˆçŒ¤‹†Žºj
- SY-10-3
- ŠgŽUMRI‚Ì—Õ°‰ž—p
–Ø@–ÎŽ÷i‡“V“°‘åŠw•úŽËüˆãŠwuÀj
- ƒVƒ“ƒ|ƒWƒEƒ€11
- _Œo“à‰Èˆã‚̃ŠƒNƒ‹[ƒg‚ÉŒq‚°‚é–¢—ˆ‚Ö‚Ì’ñŒ¾
5ŒŽ19“úi–Øj 14:45`16:45@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j
- À’·F
- “¹—E@Šwiˆ¤’mˆã‰È‘åŠw_Œo“à‰Èj
-
- ‰¡“c@—²“¿i“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj
Keynote Lecture Attracting the best and brightest to careers in neurology
Donald H. SilberbergiUniversity of Pennsylvania, USAj
- SY-11-1
- Medical Neurology/Critical Neurology
Š¡“c@“T¶i_ŒË‘åŠwˆãŠw•”•‘®•a‰@_Œo“à‰Èj
- SY-11-2
- Expert/Neurologist `—Õ°
“ŒŠC—Ñ@Š²•viO‘O‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È”]_Œo“à‰ÈŠwj
- SY-11-3
- Disease-oriented Neuroscience Researcher
–]ŒŽ@GŽ÷i–k—¢‘åŠw_Œo“à‰ÈŠwj
- ƒVƒ“ƒ|ƒWƒEƒ€12
- ‹Ø‰ŠŒ¤‹†Å‹ß‚Ìi•à
5ŒŽ19“úi–Øj 14:45`16:45@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- –Ø@³Žui“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
-
- ¼–ì@ˆêŽOi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æˆê•”j
- SY-12-1
- ‹Ø‰ŠŠÖ˜AŽ©ŒÈR‘Ì
ŒK–¼@³—²iŒcœä‹`m‘åŠwƒŠƒEƒ}ƒ`“à‰Èj
- SY-12-2
- RSRPR‘Ì—z«ƒ~ƒIƒpƒ`[
—é–Ø@d–¾iŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
- SY-12-3
- ••“ü‘̋؉Š‚Ì•a‘Ô‚Æ•p“x
—é–Ø@’¼‹Pi“Œ–k‘åŠw•a‰@_Œo“à‰Èj
- SY-12-4
- ‹Ø‰ŠŽ¡—ÂÌÅ‘Oü
´…@i“Œ‹ž‘åŠw•a‰@_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€13
- ŽŸ¢‘ãƒV[ƒPƒ“ƒT[‚É‚æ‚é_ŒoŽ¾Š³‚̉ð–¾
5ŒŽ19“úi–Øj 14:45`16:45@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j
- À’·F
- ’Ò@ÈŽŸi“Œ‹ž‘åŠw_Œo“à‰Èj
-
- ŒË“c@’BŽji_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo“à‰ÈŠw•ªŽq”]‰ÈŠwj
- SY-13-1
- ƒp[ƒ\ƒiƒ‹ƒQƒmƒ€Œ¤‹†‚̃I[ƒo[ƒrƒ…[
ŒË“c@’BŽji_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo“à‰ÈŠw•ªŽq”]‰ÈŠwj
’Ò@ÈŽŸi“Œ‹ž‘åŠw_Œo“à‰Èj
- SY-13-2
- ƒp[ƒ\ƒiƒ‹ƒQƒmƒ€‚Ìî•ñ‰ðÍFŒ»ó‚Ì®—‚Æ“W–]
X‰º@^ˆêi“Œ‹ž‘åŠwî•ñ¶–½‰ÈŠwêUj
- SY-13-3
- ˆâ“`«_ŒoŽ¾Š³‚ÌŒ¤‹†|Posterior column ataxia with retinitis pigmentosa|
ΉY@_”Vi“Œ‹ž‘åŠw_Œo“à‰Èj
- SY-13-4
- ŒÇ”«Ž¾Š³‚ÌŒ¤‹†|ƒp[ƒLƒ“ƒ\ƒ“•a
ŽOˆä@ƒi“Œ‹ž‘åŠw•a‰@_Œo“à‰Èj
- SY-13-5
- ƒp[ƒ\ƒiƒ‹ƒQƒmƒ€Œ¤‹†‚Ì—Ï—“I‰Û‘è
‰Á“¡@˜ali‹ž“s‘åŠwƒQƒmƒ€ELSIƒ†ƒjƒbƒgj
- ƒVƒ“ƒ|ƒWƒEƒ€14
- _Œo•Ï«‚ð‚Ç‚¤l‚¦‚é‚©H•a‘Ô—‰ð‚ÉŽŠ‚éÅ‹ß‚Ìi•à
5ŒŽ19“úi–Øj 14:45`16:45@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- ‘«—§@O–¾i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
-
- ŠÑ–¼@Msi—‰»ŠwŒ¤‹†Š\‘¢_Œo•a—Œ¤‹†ƒ`[ƒ€j
- SY-14-1
- ‹ÃW‘ÌŒ`¬‚©‚ç‚Ý‚½_Œo•Ï«‹@˜
ŠÑ–¼@Msi—‰»ŠwŒ¤‹†Š\‘¢_Œo•a—Œ¤‹†ƒ`[ƒ€j
- SY-14-2
- DNA‘¹C•œ‚©‚ç‚Ý‚½_Œo•Ï«‹@˜
‰ªàV@‹Ïi“Œ‹žˆã‰ÈŽ•‰È‘åŠwj
- SY-14-3
- TGF|ƒÀƒVƒOƒiƒ‹‚©‚ç‚Ý‚½_Œo•Ï«‹@˜
Ÿ–ì@‰ë‰›i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-14-4
- Žá”N«ƒp[ƒLƒ“ƒ\ƒ“•a‚Ì•a‘Ô‰ð–¾FƒCƒ“ƒXƒŠƒ“ŠJŒû‹@\‚©‚ç‚»‚Ì•aˆö‚É”—‚é
•ž•”@MFi‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
- SY-14-5
- ƒ~ƒgƒRƒ“ƒhƒŠƒA‚©‚猩‚½_Œo•Ï«‹@˜\ƒp[ƒLƒ“ƒ\ƒ“•a‚ð—á‚É\
¼“c@Œ›”Vi“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š’`”’Ž¿‘ãŽÓŒ¤‹†Žºj
- ƒVƒ“ƒ|ƒWƒEƒ€15
- ÅV‚Ì‚Ä‚ñ‚©‚ñ‚Ì•a‘Ô‚ÆŽ¡—Ãi‹¤ÃF“ú–{‚Ä‚ñ‚©‚ñŠw‰ïj
5ŒŽ19“úi–Øj 14:45`16:45@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- Œ“Žq@’¼iO‘O‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È_Œo¸_ˆãŠwuÀj
-
- ’Ò@’åriŽY‹Æˆã‰È‘åŠw_Œo“à‰Èj
- SY-15-1
- ‚Ä‚ñ‚©‚ñ‚̃LƒƒƒŠ[ƒI[ƒo[Š³ŽÒ‚Ì–â‘è
‘å’Ë@èñŽqi‰ªŽR‘åŠw•a‰@¬Ž™_Œo‰Èj
- SY-15-2
- ‚Ä‚ñ‚©‚ñ‚Ì–À‘–_ŒoŽhŒƒ—Ö@
ì‡@Œª‰îi“Œ‹ž‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_ŒoŠO‰Èj
- SY-15-3
- ‚Ä‚ñ‚©‚ñŒ¤‹†‚ÌÅ‘Oü
’r“c@º•vi‹ž“s‘åŠw•a‰@_Œo“à‰Èj
- SY-15-4
- ‚Ä‚ñ‚©‚ñŽ¡—ÂÌÅ‘Oü
d“¡@Š°Žji‹ãB‘åŠw•a‰@_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€16
- S–[ד®Š³ŽÒ‚ÌR‹ÃŒÅ—Ö@\VŽž‘ã‚ւ̑Ήž\
5ŒŽ19“úi–Øj 14:45`16:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- “àŽR@^ˆê˜Yi“Œ‹ž—Žqˆã‰È‘åŠw_Œo“à‰Èj
-
- –îâ@³Oi‘—§•a‰@‹@\‹ãBˆã—ÃZƒ“ƒ^[”]ŒŒŠÇE_Œo“à‰Èj
- SY-16-1
- S–[ד®‚ÌVƒKƒCƒhƒ‰ƒCƒ“‚Æ“úíf—Âւ̑Ήž
ŽR‰º@•ŽuiS‘ŸŒŒŠÇŒ¤‹†ŠzŠÂŠí“à‰Èj
- SY-16-2
- S–[ד®‚Æ”]ÇðÇF‹}«ŠúŽ¡—Â̎ÀÛ‚Æ–â‘è“_
–îâ@³Oi‘—§•a‰@‹@\‹ãBˆã—ÃZƒ“ƒ^[”]ŒŒŠÇE_Œo“à‰Èj
- SY-16-3
- ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ö‚ÌŠú‘Ò‚Æ–â‘è“_
“àŽR@^ˆê˜Yi“Œ‹ž—Žqˆã‰È‘åŠw_Œo“à‰Èj
- SY-16-4
- Xa‘jŠQ–ò‚ÌÅV‚̃Gƒrƒfƒ“ƒX‚Æ“W–]
’·”ö@‹B•Fi“Œ‹ž—Žqˆã‰È‘åŠw_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€17
- “«––½_ŒoŽ¾Š³‚ÌŽ¡—Ãí—ª
5ŒŽ19“úi–Øj 14:45`16:45@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j
- À’·F
- _“c@—²iŽRŒû‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_Œo“à‰Èj
-
- ’†ì@³–@i‹ž“s•{—§ˆã‰È‘åŠw_Œo“à‰ÈŠwj
Keynote Lecture Perspectives in refractory diabetic and amyloid small-fiber neuropathy
Gerard SaidiDepartment of Neurology Hospital de la Salpetriere, Francej
- SY-17-1
- –«‰ŠÇ«’E‘«‘½”ªƒjƒ…[ƒƒpƒ`[‚ÌŽ¡—Ô½‰ž«
”Ñ“‡@³”Ži–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-17-2
- ƒVƒƒƒ‹ƒR[Eƒ}ƒŠ[EƒgƒD[ƒX•a‚ÌŽ¡—Ãí—ª
’†ì@³–@i‹ž“s•{—§ˆã‰È‘åŠw_Œo“à‰ÈŠwj
- SY-17-3
- ƒNƒƒEE[£ÇŒóŒQ
ŒKŒ´@‘iç—t‘åŠw•a‰@_Œo“à‰Èj
- SY-17-4
- ŒŒ‰t_ŒoŠÖ–å‚ðƒ^[ƒQƒbƒg‚Æ‚µ‚½Ž¡—Ãí—ª
_“c@—²iŽRŒû‘åŠw•a‰@_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€18
- _Œo“ï•aŠ³ŽÒ‚Ì‘‡“IŽx‰‡
5ŒŽ20“úi‹àj 13:15`14:45@1B‰ïêi1†ŠÙ3ŠK‰ï‹cŽº131{132j
- À’·F
- Ž…ŽR@‘×li‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[j
-
- ¡ˆä@®Žui‘—§•a‰@‹@\‹{é•a‰@_Œo“à‰Èj
- SY-18-1
- “ï•aƒlƒbƒgƒ[ƒN‚Æ“ï•aŠ³ŽÒŽx‰‡
‹g—Ç@ˆêi‹ãB‘åŠw_Œo“à‰Èj
- SY-18-2
- “ï•aŠ³ŽÒ‚ÌQOL
¬X@“N•vi‘—§•a‰@‹@\” ª•a‰@j
- SY-18-3
- Ý‘î_Œo“ï•aŠ³ŽÒ‚ÌЊQŽžŽx‰‡Œv‰æ
¼àV@³–LiVŠƒ‘åŠw•a‰@”]Œ¤‹†Š—Õ°_Œo‰ÈŠw•”–å_Œo“à‰ÈŠw•ª–ìj
- SY-18-4
- u“ï•aŠ³ŽÒ‚Ìg‚¶‚è‚Âh‚ðˆç‚ÞŽx‰‡‚Ì\’z‚ÉŒü‚¯‚ÄvŒ¤‹†”ǂ̬‰Ê‚Æ“Œ–kEŠÖ“Œ‘åkЂ̌oŒ±‚𓥂܂¦‚Ä
¡ˆä@®Žui‘—§•a‰@‹@\‹{é•a‰@_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€19
- ƒOƒŠƒA×–E‚Æ_ŒoŽ¾Š³
5ŒŽ20“úi‹àj 13:15`14:45@1C‰ïêi1†ŠÙ3ŠK‰ï‹cŽº133{134j
- À’·F
- Žà‘º@–¾¶i–¼ŒÃ‰®‘åŠwŠÂ‹«ˆãŠwŒ¤‹†Š_Œo–Ɖu•ª–ìj
-
- ¼ˆä@^i‹à‘òˆã‰È‘åŠw_Œo“à‰Èj
- SY-19-1
- ƒAƒ‹ƒcƒnƒCƒ}[•a‚ƃ~ƒNƒƒOƒŠƒA
”óŒû@^li•úŽËüˆãŠw‘‡Œ¤‹†Š•ªŽqƒCƒ[ƒWƒ“ƒOŒ¤‹†ƒZƒ“ƒ^[j
- SY-19-2
- ”]‹•ŒŒ‚ƃAƒXƒgƒƒTƒCƒg
‚‹´@œÄˆêiŒcœä‹`m‘åŠw_Œo“à‰Èj
- SY-19-3
- ’E‘‚ƃIƒŠƒSƒfƒ“ƒhƒƒTƒCƒg
ˆÉ“¡@‚siUniversity of California Davis/Shriners Hospitals for Children Northern California, Department of Neurology, USAj
- ƒVƒ“ƒ|ƒWƒEƒ€20
- “«_ŒoŠ´õÇupdate
5ŒŽ20“úi‹àj 13:15`14:55@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j
- À’·F
- ‹Tˆä@‘i“ú–{‘åŠwˆãŠw•”“à‰ÈŠwŒn_Œo“à‰ÈŠw•ª–ìj
-
- …àV@‰p—mi“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@ˆãŽ•Šw‘‡Œ¤‹†‰È”]_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj
- SY-20-1
- ’Pƒƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠ´õÇ
‹Tˆä@‘i“ú–{‘åŠwˆãŠw•”“à‰ÈŠwŒn_Œo“à‰ÈŠw•ª–ìj
- SY-20-2
- HAMƒXƒyƒNƒgƒ‰ƒ€
‹v•Û“c@—´“ñiŽŽ™“‡‘åŠw“ƒEƒCƒ‹ƒX•a‘Ô§ŒäŒ¤‹†ƒZƒ“ƒ^[j
- SY-20-3
- ˆŸ‹}«d‰»«‘S”]‰Š
×–î@Œõ—ºi•Ÿ“‡Œ§—§ˆã‰È‘åŠw¬Ž™‰Èj
- SY-20-4
- is«‘½‘ƒ«”’Ž¿”]ÇiPMLj
…àV@‰p—mi“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘åŠw‰@ˆãŽ•Šw‘‡Œ¤‹†‰È”]_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj
- ƒVƒ“ƒ|ƒWƒEƒ€21
- _Œo•Ï«Ž¾Š³‚Æ”]‘²’†‚̃ŠƒnƒrƒŠG—˜_‚ÆŽÀ‘H
5ŒŽ20“úi‹àj 13:15`14:45@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- ¶‹î@ˆêŒ›i–kŠC“¹‘åŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj
-
- ‹{ˆä@ˆê˜YiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j
- SY-21-1
- ”]‘¹Œã‚Ì‹@”\‰ñ•œ‚Ì”]“à‹@\‚Æ_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“
‹{ˆä@ˆê˜YiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j
- SY-21-2
- ‹}«Šú‚©‚çŠJŽn‚·‚é”]‘²’†ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚ÆŽÀÛ
Œ´@Š°”üi‘ŠàV•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj
- SY-21-3
- _ŒoŽ¾Š³‚ɑ΂·‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚ÆŽÀ‘H
Œ´@sOi“ú–{ˆã‰È‘åŠwç—t–k‘•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€22
- “«š‹‰ºáŠQ‚ɑ΂·‚鎡—Ãí—ªi‹¤ÃF“ú–{š‹‰ºˆãŠw‰ïj
5ŒŽ20“úi‹àj 13:15`14:45@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j
- À’·F
- ˆäã@¹Œ[iŽD–yŽR‚Ìã•a‰@j
-
- “¡“‡@ˆê˜Yi•l¼ŽsƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@j
- SY-22-1
- “«š‹‰ºáŠQ‚ɑ΂·‚鎡—Ãí—ª‘˜_CƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“CŽèp
“¡“‡@ˆê˜Yi•l¼ŽsƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@j
- SY-22-2
- ”]‘²’†‚É‚æ‚éš‹‰ºáŠQ‚ɂ‚¢‚ÄWallenbergÇŒóŒQi‰„‘ŠO‘¤[Çj‚ð’†S‚É
‹“‡@•¶Žqi‹ž“s‘æˆêÔ\Žš•a‰@_Œo“à‰Èj
- SY-22-3
- ƒp[ƒLƒ“ƒ\ƒ“•aC‹ØˆÞk«‘¤õd‰»Ç‚ɑ΂·‚éš‹‰ºáŠQ‚Ì•]‰¿‚Æ‘Îô
ŽR–{@•q”Vi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€23
- _ŒoŽ¾Š³‚ɑ΂·‚é×–EŽ¡—Â̊J”`Œ»ó‚Æ“W–]
5ŒŽ20“úi‹àj 13:15`14:45@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- ‚‹´@—Ç•ãi‹ž“s‘åŠw•a‰@_Œo“à‰Èj
-
- ¼–{@¹‘×iL“‡‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È‘n¶ˆã‰ÈŠwêU•a‘Ô’T‹†ˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠwi‘æŽO“à‰Èjj
- SY-23-1
- ’†•_ŒoŽ¾Š³‚ɑ΂·‚é×–EŽ¡—Â̓W–]‚ƉۑèiƒI[ƒo[ƒrƒ…[j
‚‹´@—Ç•ãi‹ž“s‘åŠw•a‰@_Œo“à‰Èj
- SY-23-2
- iPS×–E컋Zp‚ð—p‚¢‚½_Œo•Ï«Ž¾Š³‚ÌŒ¤‹†
ˆäã@Ž¡‹vi‹ž“s‘åŠwiPS×–EŒ¤‹†Š—Õ°‰ž—pŒ¤‹†•”–åj
- SY-23-3
- _Œo•ª‰»‚Æ‘¢Žîᇫ‚©‚ç”—‚éƒqƒgiPS×–E‚Ì•iŽ¿•]‰¿
‰ª“c@—m•½iŒcœä‹`m‘åŠw¶—Šwj
- SY-23-4
- SŒ´«”]ÇðÇŠ³ŽÒ‚ɑ΂·‚鎩ŒÈœ‘’PŠj‹…‚ð—p‚¢‚½×–EŽ¡—Â̗հŽŽŒ±
“cŒû@–¾•Fi‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[”]_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€24
- ‘n–òŒ¤‹†‚ð„i‚·‚邽‚߂ɂ͉½‚ª•K—v‚©H
5ŒŽ20“úi‹àj 13:15`14:45@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- ˆ¢•”@N“ñi‰ªŽR‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È_Œo•a‘Ô“à‰ÈŠwi_Œo“à‰Èjj
-
- “c’†@ÍŒii–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-24-1
- ‹}‚ª‚Ήñ‚êF—Õ°Œ¤‹†ˆã‚ÌŒú‚¢‘w‚̈笂ÍC«—ˆ‚Ì‘n–òŒ¤‹†‚ðŽx‚¦‚é
•ŸŒ´@rˆêi‹ž“s‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã—ÉuŠw•ª–ìj
- SY-24-2
- ƒAƒJƒfƒ~ƒA‚Å‚Ìæ’[‘n–òE‘Šú’Tõ“I—Õ°ŠJ”
‹{“c@•q’ji“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È•‘®‘n¶‰ž—pˆãŠwŒ¤‹†ƒZƒ“ƒ^[j
- SY-24-3
- “ú–{‚ÆŠCŠO‚É‚¨‚¯‚é—Õ°ŽŽŒ±‚ÌŽÀî‚Æ¡Œã‚Ì“W–]
ˆêŠÛ@Ÿ•Fiˆã–ò•iˆã—Ë@Ší‘‡‹@\V–òR¸‘æŽO•”j
- ƒVƒ“ƒ|ƒWƒEƒ€25
- ‚ß‚Ü‚¢‚Ì—Õ°FÅ‹ß‚Ìi•à
5ŒŽ20“úi‹àj 13:15`14:45@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- œA£@Œ¹“ñ˜Yióƒm쑇•a‰@”]_ŒoƒZƒ“ƒ^[j
-
- •Ÿ•@•q•vi‹T“cƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[_Œo“à‰Èj
- SY-25-1
- ƒI[ƒo[ƒrƒ…[F‚ß‚Ü‚¢‚Ì—Õ°‚ð—‰ð‚µ‚悤
œA£@Œ¹“ñ˜Yióƒm쑇•a‰@”]_ŒoƒZƒ“ƒ^[j
- SY-25-2
- —Ç«”ì«“ªˆÊ‚ß‚Ü‚¢Ç\f’f‚ÆŽ¡—ÂÌi•à
—é–Ø@åÊi“Œ‹žˆã‰È‘åŠwŽ¨•@ˆôA‰ÈŠw‹³Žºj
- SY-25-3
- ”]Š²E¬”]‚ÌŒŒŠÇáŠQ‚É‚æ‚é‚ß‚Ü‚¢
é‘q@Œ’i•½’Ë‹¤Ï•a‰@_Œo“à‰Èj
- SY-25-4
- ƒqƒg‚Ì‘O’ë”玿
“à“¡@‘×i_ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@Ž¨•@ˆôA‰Èj
- SY-25-5
- ‚Ü‚Æ‚ß
•Ÿ•@•q•vi‹T“cƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€26
- •Ï«Ž¾Š³‚̃V[ƒhE‹ÃWE_Œo‰ñ˜H–Ô“`”À‰¼à‚ÌŒŸØ
5ŒŽ20“úi‹àj 13:15`14:45@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- ’·’Jì@¬li“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š”F’mǃvƒƒWƒFƒNƒgj
-
- ‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
- SY-26-1
- ˜Œ¾F‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNƒvƒƒWƒFƒNƒg‚©‚ç‚ÌŽxŽ
‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
- SY-26-2
- ƒvƒŠƒIƒ“•a‚©‚ç‚Ý‚½Š´õ‚·‚é’`”’‚Æ‚Í\Œ´“_‚Æ‚µ‚ẴvƒŠƒIƒ“•aup to date\
–k–{@“N”Vi“Œ–k‘åŠwˆãŠwŒnŒ¤‹†‰È•a‘Ô_ŒoŠwj
- SY-26-3
- _Œo•Ï«Ž¾Š³‚É‚¨‚¯‚é’`”’Šà‰¼à
’·’Jì@¬li“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š”F’mǃvƒƒWƒFƒNƒgj
- SY-26-4
- ƒnƒ“ƒ`ƒ“ƒgƒ“•a‚ł̸_áŠQ”Œ»‚É‚¨‚¯‚éƒNƒƒXƒV[ƒfƒBƒ“ƒO‰¼à\ƒvƒŠƒIƒ“•a‚©‚ç¸_E_ŒoŽ¾Š³‚Ö‚Ì“W–]\
“c’†@Œ³‰ëi—‰»ŠwŒ¤‹†Š”]‰ÈŠw‘‡Œ¤‹†ƒZƒ“ƒ^[“c’†Œ¤‹†ƒ†ƒjƒbƒgj
- ƒVƒ“ƒ|ƒWƒEƒ€27
- ƒI[ƒgƒtƒ@ƒW[‚Æ_Œo•Ï«‚ð‚ß‚®‚Á‚ÄF•a‘Ô‚©‚玡—ÂÖ
5ŒŽ20“úi‹àj 13:15`14:45@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j
- À’·F
- ¬¼@‰ë–¾i“Œ‹ž“sˆãŠw‘‡Œ¤‹†Šj
-
- ‰iˆä@‹`—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æŽl•”j
- SY-27-1
- ƒXƒgƒŒƒX‰ž“š‹@\‚Æ‚µ‚Ä‚Ì‘I‘ð“IƒI[ƒgƒtƒ@ƒW[
¬¼@‰ë–¾i“Œ‹ž“sˆãŠw‘‡Œ¤‹†Šj
- SY-27-2
- •a“IƒAƒ“ƒhƒƒQƒ“Žó—e‘̶̂‘Ì“à•ª‰ðŒn‚ð—˜—p‚µ‚½‘|“¢
‘«—§@O–¾i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-27-3
- QBP1‚ð‰ž—p‚µ‚½ˆÙíL’·ƒ|ƒŠƒOƒ‹ƒ^ƒ~ƒ“’`”’Ž¿‚Ì“ÁˆÙ“I•ª‰ð
‰iˆä@‹`—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æŽl•”j
- ƒVƒ“ƒ|ƒWƒEƒ€28
- “d‹C¶—‚©‚ç‚Ý‚½ALS‚Ì•a‘Ôupdate
5ŒŽ20“úi‹àj 15:00`17:00@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j
- À’·F
- ŒKŒ´@‘iç—t‘åŠw_Œo“à‰Èj
-
- ‰€¶@‰ëOi’é‹ž‘åŠw_Œo“à‰Èj
- SY-28-1
- ALS‚Ì“d‹C¶—Šw“If’f‚ÌŽÀÛ
‰€¶@‰ëOi’é‹ž‘åŠw_Œo“à‰Èj
- SY-28-2
- ALS‚ł͉^“®_ŒoŽ²õ‚Ì–Œ“dˆÊ•Ï“®‚ª‘å‚«‚¢
“‡’J@‰ÀŒõi“¿“‡‘åŠw•a‰@_Œo“à‰Èj
- SY-28-3
- ALS‚Ì—\Œã‹K’èˆöŽq‚Æ‚µ‚Ẳ^“®_ŒoŽ²õ–Œ‹»•±“Á«
‹àˆä@”–¾iç—t‘åŠwˆãŠw•”•‘®•a‰@_Œo“à‰Èj
- SY-28-4
- TDP-43‹§”Œ»“®•¨ƒ‚ƒfƒ‹‚É‚¨‚¯‚é•a—E“d‹C¶—
‰¡“c@—²“¿i“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€29
- Ò‘¬”]•Ï«Çupdate
5ŒŽ20“úi‹àj 15:00`17:00@2D‰ïêi2†ŠÙ2ŠK‰ï‹cŽº224j
- À’·F
- ²X–Ø@G’¼i–kŠC“¹‘åŠwˆãŠwŒ¤‹†‰È_Œo“à‰Èj
-
- ¼àV@³–LiVŠƒ‘åŠw•a‰@”]Œ¤‹†Š_Œo“à‰ÈŠw•ª–ìj
- SY-29-1
- ¬”]‹@”\‚̶—Šw“I‰ðÍFŽžŠÔ•\Œ»‚̃ƒJƒjƒYƒ€
“c’†@^Ž÷i–kŠC“¹‘åŠwˆãŠwŒ¤‹†‰È¶—ŠwuÀ”F’ms“®Šw•ª–ìj
- SY-29-2
- SCA31‚Ì•ªŽq•a‘Ô‰ð–¾
Îì@‹Ô–çi“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj
- SY-29-3
- ‚킪‘‚É‚¨‚¯‚éˆâ“`«áz«‘Ζƒáƒ‚ÌŒ»ó
‘ëŽR@‰Ã‹viŽR—œ‘åŠwˆãŠw•”_Œo“à‰ÈŠwuÀj
- SY-29-4
- ¬”]«‰^“®Ž¸’²‚ɑ΂·‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—LŒø«
‹{ˆä@ˆê˜YiX”V‹{•a‰@_ŒoƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œ¤‹†•”j
- ƒVƒ“ƒ|ƒWƒEƒ€30
- ƒAƒ~ƒƒCƒh[ƒVƒXupdate
5ŒŽ20“úi‹àj 15:00`17:00@2E‰ïêi2†ŠÙ3ŠK‰ï‹cŽº232{233j
- À’·F
- ’r“c@CˆêiMB‘åŠwˆãŠw•””]_Œo“à‰ÈCƒŠƒEƒ}ƒ`EäPŒ´•a“à‰Èj
-
- ŽR“c@³mi‹à‘ò‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]˜V‰»E_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj
- SY-30-1
- ”ñ‰Æ‘°«ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì—Õ°‚ƉuŠw
ŠÖ“‡@—ÇŽ÷iMB‘åŠwˆâ“`Žqf—Õ”j
- SY-30-2
- ‰Æ‘°«ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì—Õ°‚Æ•a—
¬’r@tŽ÷i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-30-3
- ‰Æ‘°«ƒAƒ~ƒƒCƒhƒ|ƒŠƒjƒ…[ƒƒpƒ`[iFAPj‚ɑ΂·‚éŠÌˆÚA‚Ì—L—p«‚ÆŒÀŠE
ˆÀ“Œ@—RŠì—YiŒF–{‘åŠw¶–½‰ÈŠwŒ¤‹†•”•a‘Ôî•ñ‰ðÍŠwj
- SY-30-4
- ”]ƒAƒ~ƒƒCƒhƒAƒ“ƒMƒIƒpƒ`[‚Ì—Õ°•a—
ŽR“c@³mi‹à‘ò‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]˜V‰»E_Œo•a‘ÔŠwi_Œo“à‰ÈŠwjj
- SY-30-5
- ƒAƒ~ƒƒCƒh’`”’‚Ì‘ãŽÓ‰ñ“]‚ÆŽ¡—Âɂæ‚é‘Þk
’r“c@CˆêiMB‘åŠwˆãŠw•””]_Œo“à‰ÈCƒŠƒEƒ}ƒ`EäPŒ´•a“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€31
- •Ð“ª’É‚Ì–«‰»C“‰»‚̃ƒJƒjƒYƒ€‚ÆŽ¡—Ã
5ŒŽ20“úi‹àj 15:00`17:00@2F‰ïêi2†ŠÙ3ŠK‰ï‹cŽº234j
- À’·F
- —é–Ø@‘¥GiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
-
- ’†“‡@Œ’“ñi’¹Žæ‘åŠwˆãŠw•”ˆãŠw‰È”]_Œoˆã‰ÈŠwuÀ”]_Œo“à‰ÈŠw•ª–ìj
- SY-31-1
- •Ð“ª’É–«‰»‚̃ƒJƒjƒYƒ€
—é–Ø@‘¥GiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
- SY-31-2
- •Ð“ª’É‚ÌŒo‰ßEŽ©‘R—ð
ŒÃ˜a@‹v“Ti’¹Žæ‘åŠw”]_Œo“à‰Èj
- SY-31-3
- “«–ò•¨——p“ª’É‚ÌŽ¡—Ã
à_“c@ˆêi–k—¢‘åŠwˆãŠw•”_Œo“à‰ÈŠwj
- SY-31-4
- ¸_‰ÈES—Óà‰È‚©‚ç‚̃Aƒvƒ[ƒ`
’[‹l@ŸŒhi“Œ–M‘åŠw‘åX•a‰@S—Óà‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€32
- _ŒoŽ¾Š³‚ɑ΂·‚éR‘̗Ö@
5ŒŽ20“úi‹àj 15:00`17:00@3A‰ïêi3†ŠÙ3ŠK‘Û‰ï‹cŽºj
- À’·F
- “c•½@•i‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
-
- ŽR‘º@—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†Š–ƉuŒ¤‹†•”j
- SY-32-1
- MS/NMO‚ɑ΂·‚éR‘̗Ö@‚̉”\«
ŽR‘º@—²i‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†Š–ƉuŒ¤‹†•”j
- SY-32-2
- ‹ØŽ¾Š³‚ɑ΂·‚éRƒ}ƒCƒIƒXƒ^ƒ`ƒ“R‘̗Ö@‚ÌŠJ”‚Ɖž—p
»“c@–FGiìèˆã‰È‘åŠw•a‰@_Œo“à‰ÈŠwj
- SY-32-3
- ƒAƒ‹ƒcƒnƒCƒ}[•a‚ɑ΂·‚éR‘̗Ö@
“c•½@•i‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
- SY-32-4
- ‹ØˆÞk«‘¤õd‰»Ç‚ɑ΂·‚éR‘̗Ö@
Ž½’J@^iŽ ‰êˆã‰È‘åŠw•ªŽq_Œo‰ÈŠwŒ¤‹†ƒZƒ“ƒ^[j
- ƒVƒ“ƒ|ƒWƒEƒ€33
- ƒp[ƒLƒ“ƒ\ƒ“•a‚Ì•a‘Ô‚©‚ç—Õ°update
5ŒŽ20“úi‹àj 15:00`17:00@4A‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i–kjj
- À’·F
- •ž•”@MFi‡“V“°‘åŠw”]_Œo“à‰Èj
-
- ŽR–{@Œõ—˜i쌧—§’†‰›•a‰@_Œo“à‰Èj
- SY-33-1
- •a‘Ô
’·’Jì@—²•¶i“Œ–k‘åŠw•a‰@_Œo“à‰Èj
- SY-33-2
- •a—
ꎓ¡@—SŽqi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[•a‰@—Õ°ŒŸ¸•”j
- SY-33-3
- ƒp[ƒLƒ“ƒ\ƒ“•aŽ¡—ÂÌup|to|date
”g“c–ì@‘ôi‡“V“°‘åŠwˆãŠw•”•‘®‡“V“°ˆã‰@”]_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€34
- ”][ÇFTissue clock ‚ÆReperfusion
5ŒŽ20“úi‹àj 15:00`17:00@4B‰ïêi4†ŠÙ1ŠK”’’¹ƒz[ƒ‹i“ìjj
- À’·F
- –Ø‘º@˜a”üiìèˆã‰È‘åŠw•a‰@”]‘²’†ˆãŠwj
-
- ‚‹´@œÄˆêiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
- SY-34-1
- Tissue clock ‚ÆReperfusionFBrief overview
‚‹´@œÄˆêiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
- SY-34-2
- iv-tPAŽ¡—Ã4.5ŽžŠÔ‚Ü‚Å‚Ìtime window‚ÆMRI‚Ì“WŠJ
–Ø‘º@˜a”üiìèˆã‰È‘åŠw•a‰@”]‘²’†ˆãŠwj
- SY-34-3
- ”]“®–¬ÄŠJ’ʗÖ@‚ÌŒ»ó‚Æ¡Œã
âˆä@MKi_ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@”]_ŒoŠO‰Èj
- SY-34-4
- Tissue Clock Measurement Device‚Æ‚µ‚Ä‚ÌMRS
ŒÜ\—’@”Ž’†iVŠƒ‘åŠw”]Œ¤‹†Š“‡”]‹@”\Œ¤‹†ƒZƒ“ƒ^[j
- SY-34-5
- ”][Ç‹}«ŠúŽ¡—ÂÌtherapeutic time window
ˆ¢•”@N“ñi‰ªŽR‘åŠw_Œo“à‰Èj
- ƒVƒ“ƒ|ƒWƒEƒ€35
- ‰^“®ƒjƒ…[ƒƒ“Ž¾Š³‚Ì•ªŽq•a‘Ԃ̉𖾂Ǝ¡—Ö@ŠJ”‚Ö‚Ì“W–]
5ŒŽ20“úi‹àj 15:00`17:00@4C‰ïêi4†ŠÙ3ŠK‰ï‹cŽº432j
- À’·F
- Š@—´™Zi“¿“‡‘åŠw_Œo“à‰Èj
-
- Ÿ–ì@‰ë‰›i–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-35-1
- TDP-43‚É‚æ‚é‰^“®ƒjƒ…[ƒƒ“•Ï«‚Ì•ªŽq•a‘Ô
–ì’†@—²i“Œ‹ž“sˆãŠw‘‡Œ¤‹†Šj
- SY-35-2
- Seipinopathy/Seipin/BSCL2ŠÖ˜A‰^“®ƒjƒ…[ƒƒ“Ž¾Š³\_Œo•Ï«‚É‚¨‚¯‚鬖E‘̃XƒgƒŒƒX‚Ìd—v«\
ˆÉ“Œ@‘å‰îiŒcœä‹`m‘åŠw•a‰@_Œo“à‰Èj
- SY-35-3
- Dynactin|1‚ð•W“I‚Æ‚µ‚½ŒÇ”«ALSƒ‚ƒfƒ‹‚ÌŠJ”
“c’†@ÍŒii–¼ŒÃ‰®‘åŠw_Œo“à‰Èj
- SY-35-4
- ALS ‚É‚¨‚¯‚éƒOƒŠƒAŠÖ˜A•a‘Ô
ŽR’†@G“ñi—‰»ŠwŒ¤‹†Š”]‰ÈŠw‘‡Œ¤‹†ƒZƒ“ƒ^[‰^“®ƒjƒ…[ƒƒ“•Ï«Œ¤‹†ƒ`[ƒ€j
- SY-35-5
- ŠÌ×–E‘BˆöŽq‚É‚æ‚éALS‚ɑ΂·‚éV‹KŽ¡—Ö@‚ÌŠJ”
–Ø@³Žui“Œ–k‘åŠw•a‰@_Œo“à‰Èj
ƒy[ƒWƒgƒbƒv‚Ö↑
ƒ`[ƒ€ˆã—ÃŽÀ‘HƒvƒƒOƒ‰ƒ€
- ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg
5ŒŽ17“úi‰Îj 13:00`15:30@2B‰ïêi2†ŠÙ1ŠK“WŽ¦Žº212j
1C“]“|—\–h
- À’·F
- ‹Àê@ˆèŽqi‘—§•a‰@‹@\“Œ–¼ŒÃ‰®•a‰@_Œo“à‰Èj
-
- ìˆä@[i“Œé‹Ê•a‰@_Œo“à‰Èj
“]“|—\–h‚̃ƒJƒjƒYƒ€
- ‰‰ŽÒF
- ‰œò@GNi“ŒŒäŽs—§‚Ý‚Ü‚«‰·òf—Êj
_ŒoŽ¾Š³‚É‚¨‚¯‚é“]“|‚Ì“Á’¥
- ‰‰ŽÒF
- ‹Àê@ˆèŽqi‘—§•a‰@‹@\“Œ–¼ŒÃ‰®•a‰@_Œo“à‰Èj
“]“|—\–h‘Îô‚ÆŽÀ‘H
- ‰‰ŽÒF
- ‘ºˆä@“ÖŽqi‘—§•a‰@‹@\“Œ–¼ŒÃ‰®•a‰@ŠÅŒì•”j
“]“|—\–h‚Ì‚½‚߂̃ŠƒnƒrƒŠ
- ‰‰ŽÒF
- ˆ¢•”@˜a•vi‘åã•ÛŒ’ˆã—ÑåŠwŒ¤‹†Žx‰‡ƒZƒ“ƒ^[j
- ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg
5ŒŽ17“úi‰Îj 15:45`18:15@2B‰ïêi2†ŠÙ1ŠK“WŽ¦Žº212j
2C‰h—{ŠÇ—
- À’·F
- ‹{àV@–õi‹ßX•a‰@—Õ°‰h—{•”j
-
- ŽR‰ª@˜NŽqi‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj
_ŒoŽ¾Š³Š³ŽÒ‚̉h—{ƒTƒ|[ƒg
- ‰‰ŽÒF
- ‹{àV@–õi‹ßX•a‰@—Õ°‰h—{•”j
_ŒoŽ¾Š³‚É‚¨‚¯‚é•a‘ԂƉh—{‰î“ü
- ‰‰ŽÒF
- ŽR‰ª@˜NŽqi‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj
Œo’°‰h—{–@‚ÆŒoÖ¬‰h—{–@
- ‰‰ŽÒF
- •Ð‘½@Žj–¾i‹T“c‘‡•a‰@_Œo“à‰Èj
_ŒoŽ¾Š³‚É‚¨‚¯‚éåñጂ̊Ǘ
- ‰‰ŽÒF
- ˆéŠL@‘P‘ i‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[æ’[f—Õ””畆‰Èj
- ƒe[ƒ}2@‚ŽŸ”]‹@”\áŠQ‚ɑ΂·‚éƒPƒA‚ƃŠƒnƒrƒŠ‚ÌÅ‘Oü
5ŒŽ17“úi‰Îj 14:00`18:30@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j
- À’·F
- •“c@ÍŒhi‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_Œo“à‰Èj
-
- ŽR–{@³•Fiˆ¤’mŠw‰@‘åŠwSg‰ÈŠw•”j
‚ŽŸ”]‹@”\áŠQ‚̃PƒA‚ƃŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“
- ‰‰ŽÒF
- Ží‘º@—¯”üi_ŒË‘åŠw‘åŠw‰@•ÛŒ’ŠwŒ¤‹†‰Èj
”F’mǂ̃PƒA‚ƃŠƒnƒrƒŠF_Œo“à‰È‚Ì—§ê‚©‚ç
- ‰‰ŽÒF
- ¡‘º@“OiVŠƒˆã—ÕŸŽƒ‘åŠw‘åŠw‰@ˆã—ÕŸŽƒŠwŒ¤‹†‰È•ÛŒ’ŠwêUŒ¾Œê’®ŠoŠw•ª–ìj
”F’mǂ̃PƒA‚ƃŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“G¸_‰È‚Ì—§ê‚©‚ç
- ‰‰ŽÒF
- ŽO‘º@›’iŒcœä‹`m‘åŠwˆãŠw•”¸__Œo‰Èj
Ž¸Œêǂ̃PƒA‚ƃŠƒnƒrƒŠ
- ‰‰ŽÒF
- ‘å’Î@”ü‰Ài–kŠC“¹‘åŠw‘åŠw‰@•ÛŒ’‰ÈŠwŒ¤‹†j
- ƒe[ƒ}3@CI—Ö@K“¾ƒvƒƒOƒ‰ƒ€
5ŒŽ17“úi‰Îj 14:00`16:30@2C‰ïêi2†ŠÙ2ŠK‰ï‹cŽº222{223j
- À’·F
- ›ŽìŽR@–«i–¼ŒÃ‰®‘åŠw•ÛŒ’Šw‰Èj
CI—Ö@K“¾ƒZƒ~ƒi[
- ‰‰ŽÒF
- “¹–Æ@˜a‹vi•ºŒÉˆã‰È‘åŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆãŠw‹³Žºj
- ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg
5ŒŽ18“úi…j 8:30`10:10@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j
3C_Œo‹ØŽ¾Š³‚É‚¨‚¯‚éŒÄ‹zƒPƒA
- À’·F
- ’†“‡@Fi‘—§•a‰@‹@\VŠƒ•a‰@_Œo“à‰Èj
-
- •Ÿ‰i@G•qi‘—§•a‰@‹@\“ì‹ãB•a‰@j
ŒÄ‹z•s‘S‚ɑ΂·‚éŒÄ‹zƒPƒA‘˜_
- ‰‰ŽÒF
- ’±–¼—Ñ@’¼•Fi¹˜H‰Á‘Û•a‰@ŒÄ‹zŠí“à‰Èj
‹ØƒWƒXƒgƒƒtƒB[‚É‚¨‚¯‚éŒÄ‹zƒPƒA
- ‰‰ŽÒF
- Îì@—I‰Ái‘—§•a‰@‹@\”ª‰_•a‰@¬Ž™‰Èj
ALS‚̕“IŒÄ‹zƒPƒA
- ‰‰ŽÒF
- ¬X@“N•vi‘—§•a‰@‹@\” ª•a‰@j
_Œo‹ØŽ¾Š³‚̌ċzŠíƒPƒA‚É‚¨‚¯‚é—Šw—Ö@‚Ì–ðŠ„
- ‰‰ŽÒF
- ‹e’n@–Li”]ŒŒŠÇŒ¤‹†Š”üŒ´‹L”O•a‰@_Œo“ï•aƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Èj
ŒÄ‹zƒPƒA‚É‚¨‚¯‚éŠÅŒìƒPƒA‚Ì–ðŠ„
- ‰‰ŽÒF
- ’†ŽR@—D‹Gi“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š“ï•aƒPƒAŠÅŒìŒ¤‹†•”–åj
- ƒe[ƒ}1@_ŒoŽ¾Š³‚É‚¨‚¯‚éƒPƒA‚ÌŽÀ‘H‚ƃŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg
5ŒŽ18“úi…j 10:10`11:40@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j
4CÛHš‹‰º
- À’·F
- “¡–{@•ÛŽui–¼ŒÃ‰®‘åŠwŽ¨•@ˆôA‰Èj
-
- –xŒû@—˜”Vi–k—¢‘åŠwˆã—Éq¶Šw•”ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰Èj
_Œo‹ØŽ¾Š³‚É‚¨‚¯‚éÛHEš‹‰ºáŠQ‚Ì•a‘ԂƑΉž
- ‰‰ŽÒF
- –ìè@‰€Žqi•ºŒÉˆã—ÑåŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw•”j
ÛHEš‹‰ºáŠQŠ³ŽÒ‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“`Œ¾Œê’®ŠoŽm‚Ì—§ê‚©‚ç`
- ‰‰ŽÒF
- ´…@[Žqié‹ÊŒ§‘‡ƒŠƒnƒrƒŠƒZƒ“ƒ^[Œ¾Œê’®Šo‰Èj
_ŒoŽ¾Š³‚É‚¨‚¯‚éš‹‰ºáŠQŠ³ŽÒ‚̃PƒA\ÛHEš‹‰ºáŠQŠÅŒì”F’èŠÅŒìŽt‚Ì—§ê‚©‚ç\
- ‰‰ŽÒF
- “¡X@‚Ü‚èŽqi¹—êŽO•ûŒ´•a‰@ŠÅŒì‘Š’kŽºj
š‹‰ºŽ¡—Ẫ`[ƒ€Ž¡—ÂƈãŽt‚Æ‚µ‚ẴŠƒXƒNŠÇ—
- ‰‰ŽÒF
- ’Óc@‹‘¾i•ŸˆäŒ§Ï¶‰ï•a‰@Ž¨•@ˆôA‰ÈEèò•”ŠO‰Èj
- ƒe[ƒ}4@Lee Silverman Voice TreatmentiLSVTjK“¾ƒvƒƒOƒ‰ƒ€
5ŒŽ19“úi–Øj 9:45`13:00/14:00`18:20@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j
5ŒŽ20“úi‹àj 8:30`11:50/13:00`16:30@2A‰ïêi2†ŠÙ1ŠK“WŽ¦Žº211j
ƒy[ƒWƒgƒbƒv‚Ö↑
’©‚©‚ç”Ó‚Ü‚Å_Œo“à‰È
- 1D‚æ‚‚í‚©‚éÒ‘MRI‚ÌŒ©•û
5ŒŽ18“úi…j 8:30`9:15@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ˆäã@¹Œ[iŽD–yŽR‚Ìã•a‰@Ò’ÅEÒ‘ƒZƒ“ƒ^[j
- ‰‰ŽÒF
- ‹TŽR@—²iŒ§—§‘½Ž¡Œ©•a‰@_Œo“à‰Èj
- 2D‚æ‚‚í‚©‚铪•”MRI‚ÌŒ©•û
5ŒŽ18“úi…j 9:15`10:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ŽR˜e@Œ’·iL“‡‘åŠw”]_Œo“à‰Èj
- ‰‰ŽÒF
- –ö‰º@Íi“s—§_Œo•a‰@_Œo•úŽËü‰Èj
- 3D‚æ‚‚í‚©‚éŠjˆãŠwf’f
5ŒŽ18“úi…j 10:00`10:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- •ŸŽR@G’¼i‹ž“s‘åŠw”]‹@”\‘‡Œ¤‹†ƒZƒ“ƒ^[j
- ‰‰ŽÒF
- ˆÉ“¡@Œ’Œái‘—§’·Žõˆã—ÃŒ¤‹†ƒZƒ“ƒ^[”F’mÇæiˆã—ÊJ”ƒZƒ“ƒ^[”]‹@”\‰æ‘œf’fŠJ”•”j
- 4D‚æ‚‚í‚©‚鬎™‘ãŽÓ«Ž¾Š³
5ŒŽ19“úi–Øj 8:30`9:15@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ¼–ì@ˆêŽOi‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[_ŒoŒ¤‹†ŠŽ¾•aŒ¤‹†‘æˆê•”j
- ‰‰ŽÒF
- ‘å–ì@kôi’¹Žæ‘åŠw”]_Œo¬Ž™‰Èj
- 5D‚æ‚‚í‚©‚鬔]Ž¸’²Ç
5ŒŽ19“úi–Øj 9:15`10:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ¼àV@³–LiVŠƒ‘åŠw•a‰@”]Œ¤‹†Š_Œo“à‰ÈŠw•ª–ìj
- ‰‰ŽÒF
- Îì@‹Ô–çi“Œ‹žˆã‰ÈŽ•‰È‘åŠw_Œo“à‰Èj
- 6Dƒ~[ƒgEƒUEƒGƒLƒXƒp[ƒg
5ŒŽ19“úi–Øj 10:00`11:10@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- –ö@–±i”F’mljîŒìŒ¤‹†EŒ¤C‘å•{ƒZƒ“ƒ^[j
- ‰‰ŽÒF
- Šâ“c@½i“Œ‹ž—Žqˆã‰È‘åŠw–¼—_‹³Žöj
-
- ûü‹´@ºi–¼ŒÃ‰®‘åŠw–¼—_‹³Žö/“ŒŠC’†‰›•a‰@–¼—_‰@’·j
- 7D‚æ‚‚í‚©‚éˆã—Ë@ŠíiBipapCPEG“™j
5ŒŽ19“úi–Øj 11:10`11:50@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- “’ó@—´•Fiç—t_Œo“ï•aˆã—ÃZƒ“ƒ^[j
- ‰‰ŽÒF
- ’†“‡@Fi‘—§•a‰@‹@\VŠƒ•a‰@_Œo“à‰Èj
- 8D‚æ‚‚í‚©‚é•sˆÓ‰^“®‚ÌŒ©•û
5ŒŽ19“úi–Øj 13:15`14:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ‹ß“¡@’q‘Pi˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw_Œo“à‰Èj
- ‰‰ŽÒF
- ’·’Jì@ˆêŽqi‘—§•a‰@‹@\‘Š–ÍŒ´•a‰@_Œo“à‰Èj
- 9D‚æ‚‚í‚©‚éƒp[ƒLƒ“ƒ\ƒjƒYƒ€‚𗈂·Ž¾Š³‚ÌŠÓ•Ê
5ŒŽ19“úi–Øj 14:00`14:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- –쌳@³Oiˆ¤•Q‘åŠwˆãŠw•”•‘®•a‰@–ò•¨—Ö@E_Œo“à‰Èj
- ‰‰ŽÒF
- ŽO—Ö@‰pli˜a‰ÌŽRŒ§—§ˆã‰È‘åŠw_Œo“à‰Èj
- 10D‚æ‚‚í‚©‚鎩—¥_Œo‹@”\ŒŸ¸
5ŒŽ19“úi–Øj 15:00`16:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ’·’Jì@N”Ži–¼ŒÃ‰®‘æ“ñÔ\Žš•a‰@_Œo“à‰Èj
- ‰‰ŽÒF
- š –{@‰ë–çi϶‰ï•a‰@_“Þ쌧•a‰@_Œo“à‰Èj
-
- D–Î@’q”ViŠÖ“Œ’†‰›•a‰@_Œo“à‰Èj
- 11D‚æ‚‚í‚©‚éÒ‘Ž¾Š³‚ÌŒ©•û
5ŒŽ19“úi–Øj 16:00`16:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- Š‹Œ´@–ÎŽ÷i—鎈ã—ÉȊw‘åŠw•ÛŒ’‰q¶Šw•”ˆã—ÕŸŽƒŠw‰Èj
- ‰‰ŽÒF
- ˆÀ“¡@“N˜NiˆÀéX¶•a‰@_Œo“à‰ÈCˆã—ÈÀ‘Sj
- 12D‚æ‚‚í‚©‚é—U”‹Ø“d}
5ŒŽ20“úi‹àj 8:00`9:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ›ŽìŽR@–«i–¼ŒÃ‰®‘åŠw•ÛŒ’Šw‰Èj
- ‰‰ŽÒF
- KŒ´@L•vi_ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@_Œo“à‰Èj
- 13D—Õ°ŽŽŒ±‚É‚¨‚¯‚é“ŒvŠw“Il‚¦•û
5ŒŽ20“úi‹àj 9:00`9:45@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- àV“c@GKi‘—§•a‰@‹@\‰F‘½–ì•a‰@_Œo“à‰Èj
- ‰‰ŽÒF
- ãâ@_”Vi‘åã‘åŠw—Õ°ˆãHŠw—Z‡Œ¤‹†‹³ˆçƒZƒ“ƒ^[j
- 14D‚æ‚‚í‚©‚鎡Œ±EƒRƒz[ƒgŒ¤‹†
5ŒŽ20“úi‹àj 9:45`10:30@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ¼–{@¹‘×iL“‡‘åŠw”]_Œo“à‰ÈŠwj
- ‰‰ŽÒF
- ŽR–{@°Žqi‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[”]ŒŒŠÇ“à‰Èj
- 15Dƒ~[ƒgEƒUEƒGƒLƒXƒp[ƒg
5ŒŽ20“úi‹àj 13:15`14:15@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ŽR–{@ú\Žqi“¡“c•ÛŒ’‰q¶‘åŠw–¼—_‹³Žöj
- ‰‰ŽÒF
- …–ì@”ü–Mi–k—¢‘åŠwˆãŠw•”_ŒoĶˆã—ÊwuÀj
-
- ŽÄè@_i‹ž“s‘åŠw–¼—_‹³Žöj
- 16D‚ ‚È‚½‚ÍŒ©—Ž‚Æ‚µ‚Ä‚¢‚Ü‚¹‚ñ‚©H‚±‚ñ‚È”][Ç
5ŒŽ20“úi‹àj 14:15`15:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- Ž›ŽR@–õ•viŠâŽèˆã‰È‘åŠw_Œo“à‰ÈE˜V”N‰È•ª–ìj
- ‰‰ŽÒF
- –L“c@ˆê‘¥i‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[”]ŒŒŠÇ“à‰Èj
- 17D‚æ‚‚í‚©‚é’†•_Œo•a—i1j
5ŒŽ20“úi‹àj 15:00`16:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ‹´‹l@—Ç•vi•ŸŽƒ‘º•a‰@_Œo•a—Œ¤‹†Šj
- ‰‰ŽÒF
- ‚‹´@‹ÏiVŠƒ‘åŠw”]Œ¤‹†Š•a‘Ô_Œo‰ÈŠw•”–å•a—Šwj
-
- Žá—Ñ@FˆêiO‘O‘åŠw”]_Œo•a—Šwj
- 18D‚æ‚‚í‚©‚é’†•_Œo•a—i2j
5ŒŽ20“úi‹àj 16:00`17:00@1D‰ïêi1†ŠÙ4ŠK‰ï‹cŽº141{142j
- À’·F
- ‹´‹l@—Ç•vi•ŸŽƒ‘º•a‰@_Œo•a—Œ¤‹†Šj
- ‰‰ŽÒF
- ‘ºŽR@”É—Yi“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[‚—îŽÒƒuƒŒƒCƒ“ƒoƒ“ƒNj
-
- ‹g“c@áÁ—iˆ¤’mˆã‰È‘åŠw‰Á—îˆã‰ÈŠwŒ¤‹†Šj